ImmuCell Corporation (ICCC)
Healthcare
Biotechnology
11.20 $
+1.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns ImmuCell Corporation (ICCC)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 66.3% of the shares are freely tradable; institutional investors hold 21.7%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
21.7%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
32.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
66.3%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
0.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
9Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 3.35 | 302,996 | -1.8 | 12/31/2025 |
| Vanguard Capital Management, LLC | 2.88 | 260,327 | +0.0 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 2.45 | 221,716 | +77.8 | 03/31/2026 |
| Renaissance Technologies Corp | 1.68 | 151,789 | +0.7 | 03/31/2026 |
| Cresset Asset Management, LLC | 1.50 | 135,267 | +0.0 | 03/31/2026 |
| Bleichroeder LP | 1.12 | 101,594 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 0.73 | 65,765 | -9.0 | 03/31/2026 |
| Dimensional Fund Advisors, Inc. | 0.62 | 56,030 | +3.2 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.00 | 181,077 | +0.0 | 04/30/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.88 | 79,250 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.